xRead - September 2022

Wise et al.

Page 432

Author Manuscript Author Manuscript Author Manuscript Author Manuscript Study

a Rhinasthma GS includes scores from the 3 categories of RAI, LA, and UA. b Radiolabeled Bdp <2% deposition in lungs, 20%-50% in nasal cavity, and 48%-78% swallowed in 1993 Watson et al. 1811 study. ACQ = Asthma Control Questionnaire; AR = allergic rhinitis; AUC = area under the curve; Bdp = beclomethasone dipropionate; BHR = bronchial hyper-responsiveness; CS = corticosteroid; DBRCT = double-blind randomized controlled trial; ECP = eosinophil cationic protein; FeNO = fraction of exhaled nitric oxide; FEV1 = forced expiratory volume in 1 second; FP = fluticasone propionate; GS = global summary; INCS = intranasal corticosteroid; LA = lower airway; LOE = level of evidence; MF = mometasone furoate; NBI = Nasal Blocking Index; PAQLQ = Pediatric Asthma Quality of Life Questionnaire; PAR = perennial allergic rhinitis; PC 20 and PD 20 = provocation “concentration” or “dose” of methacholine causing a 20% decrease in FEV1 (also described as PD 20 FEV 1 ); PEF = peak expiratory flow; PFT = pulmonary function test; nPIF = peak nasal inspiratory flow; QOL = quality of life; RAI = respiratory allergy impact; RCT = randomized controlled trial; SAR = seasonal allergic rhinitis; SR = systematic review; UA = upper airway.

Study Year LOE design Study groups Clinical endpoint Conclusion 2 Placebo nasal spray, then Bdp INCS 100 μ g twice daily Corren et al. 1788 1992 1b DBRCT Mild SAR and asthma (n = 18): Nasal and chest symptoms, NBI, BHR (PC 20 )

PC 20 decreased over pollen season with placebo, not Bdp. Morning NBI decreased with placebo, improved with Bdp. No difference in symptoms.

1 Placebo nasal spray (vehicle of Bdp formulation); 2 Bdp INCS

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.